Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for CARsgen Therapeutics Holdings's Median PS Value or its related term are showing as below:
HKSE:02171's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
CARsgen Therapeutics Holdings (HKSE:02171) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CARsgen Therapeutics Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
14.90
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings Median PS Value Related Terms
CARsgen Therapeutics Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings Median PS Value Chart
HKSE:02171 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARsgen Therapeutics Holdings Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CARsgen Therapeutics Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CARsgen Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARsgen Therapeutics Holdings (HKSE:02171) has a Median PS Value of HK$0.00 as of Aug. 19, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CARsgen Therapeutics Holdings and its competitors. According to the industry distribution chart, CARsgen Therapeutics Holdings ranks #999999 out of 278 companies in the Biotechnology industry.
Is CARsgen Therapeutics Holdings' Median PS Value too high?
CARsgen Therapeutics Holdings' current Median PS Value is HK$0.00. Based on the distribution chart, CARsgen Therapeutics Holdings ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARsgen Therapeutics Holdings ranks #999999 out of 278 companies for Median PS Value. This places CARsgen Therapeutics Holdings in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CARsgen Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARsgen Therapeutics Holdings's current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (HKSE:02171) has a current Median PS Value of HK$0.00. The current Median PS Value is HK$0.00. CARsgen Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (HKSE:02171), the current Median PS Value is HK$0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
32GF Score
Get the complete analysis for HKSE:02171
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02171 has been successfully added to your 
